Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Strata Critical Medical, Inc.BLDE · Entity 5512 | Director | August 01, 2025 | August 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Strata Critical Medical, Inc.
Report date August 01, 2025 · Filed August 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stock, $0.0001 par value per shareSEC Table I · non-derivative | Direct | 203,977 |
Reported balance
After 2025-08-01 transaction · row 1
1 source rowRow 1 · 2025-08-01 · Grant · Acquired 35,534 · Balance 203,977 F1: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2026 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2026 Annual Meeting of Stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2025 Filed Aug 5, 2025 22:14 UTC | Strata Critical Medical, Inc. BLDE · Entity 5512 | GrantClass A common stock, $0.0001 par value per share | 35,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001779128-25-000076 · wk-form4_1754432073.xml · nonDerivative · entry 1 Borthwick John · CIK 0001972409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,977 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2026 Annual Meeting of Stockholders. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 21:32 UTC | Strata Critical Medical, Inc. BLDE · Entity 5512 | Exercise / conversionStock Option (right to buy) · Derivative | 104,388 | $0.31 Strike: $0.31 | $32,360.28 |
DisclosureSEC source: 0001779128-24-000157 · wk-form4_1734471169.xml · derivative · entry 3 Borthwick John · CIK 0001972409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A common stock, $0.0001 par value per share · 104,388 shares Expires 2025-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 21:32 UTC | Strata Critical Medical, Inc. BLDE · Entity 5512 | SaleClass A common stock, $0.0001 par value per share | 78,291 | $4.00 | $313,250.12 |
DisclosureSEC source: 0001779128-24-000157 · wk-form4_1734471169.xml · nonDerivative · entry 2 Borthwick John · CIK 0001972409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,443 F1 · shares: Includes shares sold to cover the exercise price and estimated tax liability arising in connection with the exercise of expiring stock options. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.955 to $4.075, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 21:32 UTC | Strata Critical Medical, Inc. BLDE · Entity 5512 | Exercise / conversionClass A common stock, $0.0001 par value per share | 104,388 | $0.31 | $32,360.28 |
DisclosureSEC source: 0001779128-24-000157 · wk-form4_1734471169.xml · nonDerivative · entry 1 Borthwick John · CIK 0001972409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 15:49 UTC | Strata Critical Medical, Inc. BLDE · Entity 5512 | GrantClass A common stock, $0.0001 par value per share | 15,703 | $0.00 | $0.00 |
DisclosureSEC source: 0001779128-24-000107 · wk-form4_1723564153.xml · nonDerivative · entry 2 Borthwick John · CIK 0001972409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,346 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2025 Annual Meeting of Stockholders. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 15:49 UTC | Strata Critical Medical, Inc. BLDE · Entity 5512 | GrantClass A common stock, $0.0001 par value per share | 42,826 | $0.00 | $0.00 |
DisclosureSEC source: 0001779128-24-000107 · wk-form4_1723564153.xml · nonDerivative · entry 1 Borthwick John · CIK 0001972409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,643 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2025 Annual Meeting of Stockholders. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 21:42 UTC | Strata Critical Medical, Inc. BLDE · Entity 5512 | PurchaseClass A common stock, $0.0001 par value per share | 7,743 | $2.97 | $22,995.94 |
DisclosureSEC source: 0001779128-24-000075 · wk-form4_1718228532.xml · nonDerivative · entry 1 Borthwick John · CIK 0001972409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,817 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.965 to $2.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| August 08, 2023 Filed Aug 9, 2023 21:30 UTC | Strata Critical Medical, Inc. BLDE · Entity 5512 | GrantClass A common stock, $0.0001 par value per share | 1,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001779128-23-000088 · wf-form4_169161658548863.xml · nonDerivative · entry 4 Borthwick John · CIK 0001972409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,074 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| August 08, 2023 Filed Aug 9, 2023 21:30 UTC | Strata Critical Medical, Inc. BLDE · Entity 5512 | GrantClass A common stock, $0.0001 par value per share | 12,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001779128-23-000088 · wf-form4_169161658548863.xml · nonDerivative · entry 3 Borthwick John · CIK 0001972409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,827 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| August 08, 2023 Filed Aug 9, 2023 21:30 UTC | Strata Critical Medical, Inc. BLDE · Entity 5512 | GrantClass A common stock, $0.0001 par value per share | 31,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001779128-23-000088 · wf-form4_169161658548863.xml · nonDerivative · entry 2 Borthwick John · CIK 0001972409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,356 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| August 08, 2023 Filed Aug 9, 2023 21:30 UTC | Strata Critical Medical, Inc. BLDE · Entity 5512 | GrantClass A common stock, $0.0001 par value per share | 31,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001779128-23-000088 · wf-form4_169161658548863.xml · nonDerivative · entry 1 Borthwick John · CIK 0001972409 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,178 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.